| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
|
Medicine details |
|
| Medicine name | ticagrelor (Brilique®) |
| Formulation | 60 mg, 90 mg film-coated tablet |
| Reference number | 922 |
| Indication | Co-administrated with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/02/2016 |
| NICE guidance | TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |